S&P 500
7,548.20
-0.02%
Dow Jones
52,530.70
+0.03%
Nasdaq 100
29,738.60
-0.04%
Russell 2000
2,990.36
-0.01%
FTSE 100
10,480.00
-0.33%
Nikkei 225
68,877.20
-0.22%

Health and Healthcare

Arena Files for European Drug Review (ARNA, VVUS, OREX)

Photo of Paul Ausick
By Paul Ausick Published

Invalid Image
Drug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) announced that its application to sell its lorcaserin weight-loss drug in Europe has been accepted by the Europe Medicines Agency. This is the first step toward a full review of the drug’s acceptability for the European market.

The company also said that it had scheduled a meeting with the US Food and Drug Administration for May 10th to discuss resubmission of the company’s new drug application in the US. Lorcaserin is one of three weight-loss drugs currently in the mix for FDA approval. Qnexa from Vivus Inc. (NASDAQ: VVUS) and Contrave from Orexigen Therapeutics Inc. (NASDAQ: OREX) are the others.

Arena’s shares are up nearly 17% this morning, at $2.81 after posting a new 52-week high of $2.88 earlier. The 52-week low is $1.21.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Arena Pharma Soars on FDA Approval
Chris Lange |

Arena Pharma Soars on FDA Approval

Arena Pharmaceuticals saw its shares jump in Monday’s session on news of an U.S. Food and Drug Administration (FDA) approval.

Douglas A. McIntyre |

Arena’s Real Issue: Drugs Vs. Gym & Behavior Modification (ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is getting shelled this morning.  The company released “positive study data” this morning on trials…

Top 6 BioPharma Movers of the Week
Chris Lange |

Top 6 BioPharma Movers of the Week

These biotech companies stood out from the rest with incredible gains or losses over the course of the past week.

Jon C. Ogg |

Is There Finally a Winner in the Crowded Obesity Drug Market?

ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

Paul Ausick |

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

ThinkstockDrug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) has withdrawn its application for European regulatory approval of its weight-loss drug Belviq.…

Douglas A. McIntyre |

What Options Trading Signals For Arena Pharmaceuticals’ Lorcaserin Safety Review (ARNA)

Business Week noted Arena Pharmaceuticals Inc. (NASDAQ:ARNA) as one of its three "Inside Wall Street" weekly stock picks this morning,…

Douglas A. McIntyre |

Today’s Breakout Stocks: High And Low

For today’s winners and losers, two of the four companies on the lists today are pharmaceutical companies, moving on action…

CRISPR Wins FDA Approval for Human Trials
Chris Lange |

CRISPR Wins FDA Approval for Human Trials

CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration…

Why This Hairy Cell Leukemia Treatment Could Be Big in Europe
Chris Lange |

Why This Hairy Cell Leukemia Treatment Could Be Big in Europe

Innate Pharma shares jumped on Thursday after the firm announced that the European Medicines Agency has accepted the Marketing Authorization…

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 26,398,547
Norwegian Cruise Line
NCLH • Vol: 17,598,302
Lam Research
LRCX • Vol: 12,109,308
Invesco
IVZ • Vol: 4,557,367
AMD
AMD • Vol: 26,866,096

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
APA
APA • Vol: 4,397,644
New Pluto Global
PSKY • Vol: 18,870,798
Costco
COST • Vol: 4,541,045
Cincinnati Financial
CINF • Vol: 2,196,176